Basic Information
| RNALocate ID: | RLID:11003511 |
| RNA Symbol: | hsa-miR-671-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-671-5p |
| RNA ID: | miRBase:MIMAT0003880 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20615901 |
| Tissue/Cell Line: | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) |
| Method: | Microarray|RT-PCR |
|
Originally published in Nucleic Acids Res. Wang K, et al, 2010. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | These observations of miRNA distribution demonstrate that the miRNA export system in the cells must somehow be able to target specific miRNAs to specific extracellular structures, but does not exclusively channel specific miRNAs to a given fraction. There are, however, some miRNAs that are found in the supernatant almost to the exclusion of all other fractions (miR-219 in A549 culture medium, Figure 4b, for example). Another significant observation from this data is that even though we showed that the two cell lines studied here export a similar spectrum of miRNAs (Figure 1b) the distributions of miRNAs from the two cell lines demonstrate clear differences, as shown in Figure 4b and c. For example, miR-145 is present at very low levels in HepG2 derived microvesicles (Figure 4c), while the same miRNA is present at significant levels in both A549 derived microvesicles and exosomes (Figure 4b). On the other hand, there are some miRNAs, notably those that are almost uniformly distributed among the fractions, with the same distribution no matter which cell-line is the source. These observations certainly indicate the degree of complexity of this export system that will bear further investigation. Data are collected from Figure 4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002537 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002538 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002539 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11003506 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11003507 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11003508 | Exosome | Plasma | 23663360 |
| RLID:11003509 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11003510 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11003512 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000555 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine | |
| RLID-D:11001431 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-671-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-66365 |
| MNDR | hsa-miR-671-5p | Oral squamous cell carcinoma | MNDR-E-MI-66366 |
| MNDR | hsa-miR-671-5p | B cell lymphoma of malt type | MNDR-E-MI-66367 |
| MNDR | hsa-miR-671-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-66368 |
| MNDR | hsa-miR-671-5p | Lymphoma | MNDR-E-MI-66369 |
| MNDR | hsa-miR-671-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-66370 |
| MNDR | hsa-miR-671-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-66371 |
| MNDR | hsa-miR-671-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-66372 |
| MNDR | hsa-miR-671-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-66373 |
| MNDR | hsa-miR-671-5p | Her2-receptor positive breast cancer | MNDR-E-MI-66374 |
| MNDR | hsa-miR-671-5p | Breast cancer luminal | MNDR-E-MI-66375 |
| MNDR | hsa-miR-671-5p | Prostate cancer | MNDR-E-MI-66376 |
| MNDR | hsa-miR-671-5p | Gastric cancer | MNDR-E-MI-66377 |
| MNDR | hsa-miR-671-5p | Alzheimer disease | MNDR-E-MI-66378 |
| MNDR | hsa-miR-671-5p | Intracranial aneurysm | MNDR-E-MI-66379 |
| MNDR | hsa-miR-671-5p | Lung cancer | MNDR-E-MI-66380 |
| MNDR | hsa-miR-671-5p | Parkinson disease | MNDR-E-MI-66381 |
| MNDR | hsa-miR-671-5p | Breast cancer | MNDR-E-MI-66382 |
| MNDR | hsa-miR-671-5p | Pituitary neoplasms | MNDR-E-MI-66383 |
| MNDR | hsa-miR-671-5p | Pancreatic cancer | MNDR-E-MI-66384 |
| MNDR | hsa-miR-671-5p | Melanoma | MNDR-E-MI-66385 |
| MNDR | hsa-miR-671-5p | Nephroblastoma | MNDR-E-MI-66386 |
| MNDR | hsa-miR-671-5p | Colon cancer | MNDR-E-MI-66387 |
| MNDR | hsa-miR-671-5p | Colon adenocarcinoma | MNDR-E-MI-66388 |
| MNDR | hsa-miR-671-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-66389 |
| MNDR | hsa-miR-671-5p | Familial ovarian cancer | MNDR-E-MI-66390 |
| MNDR | hsa-miR-671-5p | Prostate adenocarcinoma | MNDR-E-MI-66391 |
| MNDR | hsa-miR-671-5p | Carcinoma ductal breast | MNDR-E-MI-66392 |
| MNDR | hsa-miR-671-5p | Invasive ductal carcinoma | MNDR-E-MI-66393 |
| MNDR | hsa-miR-671-5p | Glioblastoma | MNDR-E-MI-66394 |
| MNDR | hsa-miR-671-5p | Glioma | MNDR-E-MI-66395 |
| MNDR | hsa-miR-671-5p | Chordoma | MNDR-E-MI-66396 |
| MNDR | hsa-miR-671-5p | Osteosarcoma | MNDR-E-MI-66397 |
| MNDR | hsa-miR-671-5p | Breast carcinoma | MNDR-E-MI-66398 |
| MNDR | hsa-miR-671-5p | Gastric adenocarcinoma | MNDR-E-MI-66399 |
| MNDR | hsa-miR-671-5p | Pituitary adenoma | MNDR-E-MI-66400 |
| MNDR | hsa-miR-671-5p | Lung squamous cell carcinoma | MNDR-E-MI-66401 |
| MNDR | hsa-miR-671-5p | Lung adenocarcinoma | MNDR-E-MI-66402 |
| MNDR | hsa-miR-671-5p | Thyroid carcinoma | MNDR-E-MI-66403 |
| MNDR | hsa-miR-671-5p | Bladder urothelial carcinoma | MNDR-E-MI-66404 |
| MNDR | hsa-miR-671-5p | Carcinoma renal cell | MNDR-E-MI-66405 |
| MNDR | hsa-miR-671-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-66406 |
| MNDR | hsa-miR-671-5p | Renal clear cell carcinoma | MNDR-E-MI-66407 |
| MNDR | hsa-miR-671-5p | Biliary tract cancer | MNDR-E-MI-66408 |
| MNDR | hsa-miR-671-5p | Esophageal cancer | MNDR-E-MI-66409 |
| MNDR | hsa-miR-671-5p | Prolactinoma | MNDR-E-MI-66410 |
| MNDR | hsa-miR-671-5p | Lung small cell carcinoma | MNDR-E-MI-66411 |
| MNDR | hsa-miR-671-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-66412 |
| MNDR | hsa-miR-671-5p | Adenoma | MNDR-E-MI-66413 |
| MNDR | hsa-miR-671-5p | Breast invasive carcinoma | MNDR-E-MI-66414 |
| MNDR | hsa-miR-671-5p | Progressive supranuclear palsy | MNDR-E-MI-66415 |
| MNDR | hsa-miR-671-5p | Hepatocellular carcinoma | MNDR-E-MI-66416 |
| MNDR | hsa-miR-671-5p | Embryonal cancer | MNDR-E-MI-66417 |
| MNDR | hsa-miR-671-5p | Familiar ovarian carcinoma | MNDR-E-MI-66418 |
| MNDR | hsa-miR-671-5p | B-cell lymphoma | MNDR-E-MI-66419 |
| MNDR | hsa-miR-671-5p | Malignant pleural mesothelioma | MNDR-E-MI-66420 |
| MNDR | hsa-miR-671-5p | Retinoblastoma | MNDR-E-MI-66421 |
| MNDR | hsa-miR-671-5p | Hodgkin lymphoma | MNDR-E-MI-66422 |
| MNDR | hsa-miR-671-5p | Skin cutaneous melanoma | MNDR-E-MI-66423 |
| MNDR | hsa-miR-671-5p | Skin melanoma | MNDR-E-MI-66424 |
| MNDR | hsa-miR-671-5p | Colorectal cancer | MNDR-E-MI-66425 |
| MNDR | hsa-miR-671-5p | Nasopharynx carcinoma | MNDR-E-MI-66426 |
| MNDR | hsa-miR-671-5p | Multiple myeloma | MNDR-E-MI-66427 |
| MNDR | hsa-miR-671-5p | Nasopharyngeal cancer | MNDR-E-MI-66428 |
| MNDR | hsa-miR-671-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-66429 |
| MNDR | hsa-miR-671-5p | Stroke lacunar | MNDR-E-MI-66430 |
| MNDR | hsa-miR-671-5p | Breast cancer her3+ negative | MNDR-E-MI-66431 |
| MNDR | hsa-miR-671-5p | Tubulovillous adenoma | MNDR-E-MI-66432 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CD44 | Homo sapiens | RR00301721 |
TOP